Sort
82,697 grants matching “vaccine development”
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever
$1,345,347Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2017 · AI
Lactobacilli as a Delivery Vehicle for Microbicides
$1,345,292Osel, Inc. · U19 · FY2005 · AI
Structural studies of native-like SOSIP trimers
$1,345,161Ian A Wilson · Weill Medical Coll Of Cornell Univ · P01 · FY2016 · AI
Cornell Clinical Trials Unit
$1,345,095Roy M Gulick · Weill Medical Coll Of Cornell Univ · U01 · FY2009 · AI
Improving the Outcome of Patients with Chronic Myeloid Leukemia Through Medi
$1,344,917Jorge E Cortes · University Of Tx Md Anderson Can Ctr · P01 · FY2014 · CA
National Resource for Automated Molecular Microscopy
$1,344,865Bridget Olivia Carragher · New York Structural Biology Center · P41 · FY2020 · GM
National Resource for Automated Molecular Microscopy
$1,344,865Bridget Olivia Carragher · New York Structural Biology Center · P41 · FY2019 · GM
National Resource for Automated Molecular Microscopy
$1,344,865Jeffrey S Kieft · New York Structural Biology Center · P41 · FY2021 · GM
Alphavirus Replicon Vaccines against Botulinum Neurotox*
$1,344,570Alphavax Human Vaccines, Inc. · U01 · FY2003 · AI
Novel adjuvants acting through TLR2, TLR5 and TLR7 receptors
$1,344,542Sunil David · University Of Kansas Lawrence · N01 · FY2013 · AI
MACROPHAGES, DENDRITIC CELLS AND PATHOGENS
$1,344,411Weill Medical College Of Cornell Univ · P01 · FY2004 · AI
MPOPHC: Integrating human risk perception and social processes into policy responses in an epidemiological model
$1,344,200Brian Beckage · University Of Vermont & State Agricultural College · · FY2024 · MPS
Task 01/F01:Safety, Toxicology and Pharmacology Testing for Therapeutics
$1,343,985Sri International · N01 · FY2009 · AI
INNATE IMMUNE RESPPONSE TO MICROBIAL INFECTION
$1,343,563University Of Iowa · P01 · FY2002 · AI
Development of Novel Immunogens for Vaccines to HIV-1
$1,343,498Robert Gerald Whalen · Maxygen, Inc. · P01 · FY2009 · AI
Viral and Host Determinants of Infant and Childhood Allergy and Asthma
$1,343,390Ray Stokes Peebles · Vanderbilt University Medical Center · U19 · FY2020 · AI
Core A: Husbandry & Management Core
$1,343,177Cassandra Cullin · Oregon Health & Science University · U42 · FY2025 · OD
Fox COBRE Phase II Admin Core
$1,343,022Joseph M Fox · University Of Delaware · P20 · FY2024 · GM
Recombinant Virus Vaccines
$1,342,916Bernard Moss · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Structural characterization of OM proteins from Gram-negative pathogens
$1,342,753Susan Buchanan · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Virus biology scientific research support component
$1,342,549Beatrice H Hahn · Duke University · UM1 · FY2015 · AI
Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines
$1,342,548Stefan H.i. Kappe · Seattle Children'S Hospital · U01 · FY2021 · AI
Mechanisms Of Humoral Evasion
$1,342,421Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Immunology, virology, and epidemiology of flaviviruses and other emerging viruses
$1,342,411Leah Katzelnick · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Dendritic Cell Biology and Therapy
$1,341,490Olivera J Finn · University Of Pittsburgh At Pittsburgh · P01 · FY2006 · CA